Phase 3 study for people with Hypertension

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Alnylam Pharmaceuticals
Registry number NCT07181109
Started 6 September 2025 Today 16 October 2026 Estimated completion 23 September 2030

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Clinical Trial Site Auchenflower QLD Recruiting
Clinical Trial Site Brisbane QLD Not yet recruiting
Clinical Trial Site Brookvale NSW Recruiting
Clinical Trial Site Castle Hill NSW Recruiting
Clinical Trial Site Clayton VIC Recruiting
Clinical Trial Site Concord NSW Recruiting
Clinical Trial Site Douglas QLD Recruiting
Clinical Trial Site Gosford NSW Recruiting
Clinical Trial Site Kogarah NSW Recruiting
Clinical Trial Site Leabrook SA Recruiting
Clinical Trial Site Merewether NSW Completed
Clinical Trial Site Milton QLD Recruiting
Clinical Trial Site Sippy Downs QLD Recruiting
Clinical Trial Site Southport QLD Recruiting
Clinical Trial Site Southport QLD Recruiting
Clinical Trial Site St Albans VIC Recruiting
Clinical Trial Site Tarragindi QLD Recruiting
Clinical Trial Site Waitara NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 11000

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Is 18 years or older for patients with established cardiovascular disease (CVD)

* Is 55 years or older for patients with high risk for CVD

* Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD

* Has treated hypertension on stable therapy with at least 2 standard of care antihypertensive medications, one of which must be a thiazide, thiazide-like, or loop diuretic

Exclusion Criteria:

* Has known history of secondary hypertension

* Has symptomatic orthostatic hypotension

* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3×upper limit of normal (ULN)

* Has total serum bilirubin \>1.5×ULN

* Has international normalized ratio (INR) \>1.5

* Has serum potassium \>4.8 mEq/L

* Has estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m\^2

Dates on the record

Started 6 September 2025
Estimated completion 23 September 2030
Registry last updated 15 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 15 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.